Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and oxaliplatin (eloxatin; GemOx; R-GemOx+Atezo) could be a well-tolerated and effective treatment option in non-Hodgkin lymphoma.
Areas for further research suggested by Xin Hu, PhD, MSPH, include examining differences in telemental health uptake between new and existing patients and exploring how these differences vary across demographic subgroups.
The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.
In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric alopecia areata and highlights the need for personalized treatment approaches based on Janus kinase inhibitor responses.
Lawrence F. Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the effectiveness of ruxolitinib cream as a nonsteroidal topical treatment for atopic dermatitis, its potential to reduce the need for systemic therapies, and the significant role of the skin microbiome in disease management.
As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in shaping the future of patient care, according to experts from Komodo Health and SmarterDx.
The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Priscilla Tsondai, MD, MPH, breaks down top care gaps as opportunities for care improvement.
Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Vaccine hesitancy and higher rates of school vaccine exemptions increases the risk of outbreaks of preventable diseases, creating a significant health risk for vulnerable populations.
Incorporating dynamic pricing into cost-effectiveness analysis could offer significant benefits for equity in health care.
Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic methods for metabolic dysfunction–associated steatohepatitis (MASH).
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
The second Trump administration is expected to bring changes to Medicaid, Medicare Advantage, and the health insurance exchanges, as well as highlight the Make America Healthy Again (MAHA) movement, speakers at the Value-Based Insurance Design Summit said.
The study could open the door to potential novel therapeutic targets.
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute to design and test novel delivery models for HIV services.
These abstracts highlight the compounded challenges people with HIV face.
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a combination antiretroviral therapy (ART) in its long-acting injectable form.
Michelle Hessen, OD, spoke about the results of a new study evaluating the efficacy of cyclosporine ophthalmic solution 0.09% in patients with dry eye.
There is insufficient evidence to support exclusive enteral nutrition as an adjunctive therapy for active ulcerative colitis, despite its good tolerability and low discontinuation rates, according to a systematic review.
Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Flood exposure was more strongly associated with increased health care use and cost during the summer months and among Medicare beneficiaries aged 85 or older.
Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples living in Kenya.
The topical treatment had no significant effect on total or central corneal fluorescence staining score.
New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Patients in Washington, DC, and San Francisco had minimal early uptake and adherence to doxycycline postexposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
When patients switched to either fostemsavir or the combination of dolutegravir/lamivudine (DTG/3TC), suppression was maintained in most patients.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
